LTFS
KRYS icon

Ladenburg Thalmann Financial Services’s Krystal Biotech KRYS Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$7K Buy
+125
New +$6.13K ﹤0.01% 4641

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ladenburg Thalmann Financial Services's KRYS Position: Q4 2019 in Review

Ladenburg Thalmann Financial Services opened a new position in Krystal Biotech (KRYS) in Q4 2019: 125 shares worth $7K. The stake represents ﹤0.01% of the portfolio and ranks #4641 among its holdings.

90 funds tracked by Wall St. Rank hold KRYS as of Q4 2019.

  • Ladenburg Thalmann Financial Services held 125 shares of Krystal Biotech worth $7K as of Q4 2019.
  • Krystal Biotech was a new Ladenburg Thalmann Financial Services position in Q4 2019.
  • Krystal Biotech made up ﹤0.01% of Ladenburg Thalmann Financial Services's portfolio in Q4 2019, its #4641 holding.
  • 90 funds tracked by Wall St. Rank held Krystal Biotech as of Q4 2019.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q4 2019, filed 14 Feb 2020.